Recombinant IL13 (Abrezekimab Biosimilar) antibody
Quick Overview for Recombinant IL13 (Abrezekimab Biosimilar) antibody (ABIN7676010)
Target
Antibody Type
Reactivity
Host
Clonality
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-IL-13 Reference Antibody (abrezekimab)
-
Sequence
- QVTLKESGPV LVKPTETLTL TCTVSGFSLT NYHVQWIRQP PGKALEWLGV MWSDGDTSFN SVLKSRLTIS RDTSKSQVVL TMTNMDPVDT ATYYCARDGT IAAMDYFDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSC,DIQMTQSPSS LSASVGDRVT ITCLASEDIS NYLAWYQQKP GKAPKLLIYH TSRLQDGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYRFPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Characteristics
- Anti-IL-13 Reference Antibody (abrezekimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: IL-13 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- IL13 (Abrezekimab Biosimilar)
-
Alternative Name
- IL-13 (Abrezekimab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- P35225
Target
-